[go: up one dir, main page]

IDEAS home Printed from https://ideas.repec.org/p/hal/journl/hal-02196029.html
   My bibliography  Save this paper

Market Valuation of FDA Orphan Drug Regulatory Events

Author

Listed:
  • Dimitrios Kourouklis
  • Philippe Gorry

    (GREThA - Groupe de Recherche en Economie Théorique et Appliquée - UB - Université de Bordeaux - CNRS - Centre National de la Recherche Scientifique)

Abstract
The US Orphan Drug (OD) Act was implemented in 1983 with the aim to incentivize research and development (R&D) for rare diseases. However, there is lack of empirical evidence on investigating any underlying effects and implications of such policies. The aim of this paper is to identify and measure the financial impact that is created, due to announcements, which are related to an FDA orphan drug i) designation, ii) market approval, and iii) end of exclusivity. To address our research question, we exploit the efficient market hypothesis, and therefore we use an event-study methodology, which is frequently applied in the finance literature. Our sample covers 730 events with non-missing returns for 146 firms in the period between 1984 and 2018. Specifically, 260 events are related to orphan designation, 317 are market approval events and 153 are the events related to end of exclusivity. For the construction and the analyses of our dataset, we utilized the FDA Orphan Drug Product designation database, and the Wharton Research Database (WRDS) database. Our findings suggest that OD market approval decisions result abnormal returns and cause increase on the stock prices. On the other hand, we do not find any significant effect, when the events of orphan drug designation and exclusivity end are considered. Overall, our results indicate that stock-market investors react positively to the OD market launch even if this therapeutic class addresses niche market. Therefore, OD status incentives, such as the seven year market exclusivity, as well as the tax-credit, might play an important role for forming the positive perceptions of the stock-market investors. However, this happens only when the regulatory provisions are effective i.e. the market approval. Apart from these, investors do not react to the events of OD designation, because they take into consideration the costs and the uncertainty of a drug R&D. Finally, the fact that the stock market does not negatively react to the end of OD market exclusivity would imply that firms do not rely on the OD market exclusivity, but on their patent protection, to secure their effective market monopoly as was recently suggested in the literature.

Suggested Citation

  • Dimitrios Kourouklis & Philippe Gorry, 2019. "Market Valuation of FDA Orphan Drug Regulatory Events," Post-Print hal-02196029, HAL.
  • Handle: RePEc:hal:journl:hal-02196029
    as

    Download full text from publisher

    To our knowledge, this item is not available for download. To find whether it is available, there are three options:
    1. Check below whether another version of this item is available online.
    2. Check on the provider's web page whether it is in fact available.
    3. Perform a search for a similarly titled item that would be available.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Sangha, Kamaljit K & Evans, Jay & Edwards, Andrew & Russell-Smith, Jeremy & Fisher, Rohan & Yates, Cameron & Costanza, Robert, 2021. "Assessing the value of ecosystem services delivered by prescribed fire management in Australian tropical savannas," Ecosystem Services, Elsevier, vol. 51(C).
    2. Rui de S. Camposinhos & Maria do Rosário Oliveira, 2019. "A Dynamic Approach to the Cost Method in Real Estate Appraisal," Journal of Finance and Investment Analysis, SCIENPRESS Ltd, vol. 8(4), pages 1-1.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:hal:journl:hal-02196029. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: CCSD (email available below). General contact details of provider: https://hal.archives-ouvertes.fr/ .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.